ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
5,525.21
0.74%
US Tech 100
18,919.76
1.21%
Dow Jones
40,113.50
0.05%
Brent Oil
66.025
0.00%
Bitcoin
94,196.40
-0.55%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Neumora Therapeutics Inc (NMRA) Quote

Neumora Therapeutics Inc

Neumora Therapeutics Inc (NMRA)

NASDAQ
0.7575
0.008
(1.07%)
Closed April 26 4:00PM
Delayed by 15 minutes
0.7692
0.0117
(1.54%)
After Hours: 7:56PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.7692
Bid
0.751
Ask
0.80
Volume
911,331
0.7284 Day's Range 0.7647
0.6211 52 Week Range 17.1874
Market Cap
124.594M
Previous Close
0.7495
Open
0.7522
Last Trade
1
@
0.7692
Last Trade Time
Financial Volume
$ 677,214
VWAP
0.743104
Average Volume (3m)
1,313,495
Shares Outstanding
161,978,923
Dividend Yield
-
PE Ratio
-0.50
Earnings Per Share (EPS)
-1.51
Revenue
-
Net Profit
-243.79M

About Neumora Therapeutics Inc

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, ... Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.neumoratx.com.
Headquarters
New Castle, Delaware, USA
Founded
-
Neumora Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker NMRA. The last closing price for Neumora Therapeutics was $0.75. Over the last year, Neumora Therapeutics shares have traded in a share price range of $ 0.6211 to $ 17.1874.

Neumora Therapeutics currently has 161,978,923 shares outstanding. The market capitalization of Neumora Therapeutics is $121.40 million. Neumora Therapeutics has a price to earnings ratio (PE ratio) of -0.50.

Ask ADVFN Intelligence (AI)

NMRA Latest News

More News

Form PRE 14A - Other preliminary proxy statements
Edgar (US Regulatory)
April 11 2025
NMRA (1.07%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
March 27 2025
NMRA (1.07%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.128820.11242973140.64040.80.6329818790.7128791CS
4-0.3208-29.43119266061.091.1250.621111004840.76520948CS
12-1.1608-60.14507772021.932.010.621113134951.33756811CS
26-12.2908-94.110260336913.0614.090.621120987873.50431659CS
52-8.3608-91.57502738239.1317.18740.621114477975.88833033CS
156-15.7308-95.338181818216.5210.621110577707.07856668CS
260-15.7308-95.338181818216.5210.621110577707.07856668CS

NMRA - Frequently Asked Questions (FAQ)

What is the current Neumora Therapeutics share price?
The current share price of Neumora Therapeutics is $ 0.7692
How many Neumora Therapeutics shares are in issue?
Neumora Therapeutics has 161,978,923 shares in issue
What is the market cap of Neumora Therapeutics?
The market capitalisation of Neumora Therapeutics is USD 121.4M
What is the 1 year trading range for Neumora Therapeutics share price?
Neumora Therapeutics has traded in the range of $ 0.6211 to $ 17.1874 during the past year
What is the PE ratio of Neumora Therapeutics?
The price to earnings ratio of Neumora Therapeutics is -0.5
What is the reporting currency for Neumora Therapeutics?
Neumora Therapeutics reports financial results in USD
What is the latest annual profit for Neumora Therapeutics?
The latest annual profit of Neumora Therapeutics is USD -243.79M
What is the registered address of Neumora Therapeutics?
The registered address for Neumora Therapeutics is 1209 ORANGE STREET, WILMINGTON 19801, NEW CASTLE, DELAWARE
What is the Neumora Therapeutics website address?
The website address for Neumora Therapeutics is www.neumoratx.com.
Which industry sector does Neumora Therapeutics operate in?
Neumora Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WWWW International Inc
$ 0.395
(167.62%)
223.58M
OMEXOdyssey Marine Exploration Inc
$ 1.4979
(75.79%)
285.65M
RTCBaijiayun Group Ltd
$ 0.3244
(74.88%)
263.23M
GREEGreenidge Generation Holdings Inc
$ 1.3197
(53.92%)
5.84M
SXTCChina SXT Pharmaceuticals Inc
$ 2.28
(44.30%)
38.04M
CGTLCreative Global Technology Holdings Ltd
$ 1.5197
(-75.09%)
3.88M
TOIIWOncology Institute Inc
$ 0.1015
(-40.22%)
156.14k
COEPCoeptis Therapeutics Holdings Inc
$ 7.70
(-38.25%)
716.99k
INTSIntesity Therapeutics Inc
$ 0.56
(-37.78%)
3.21M
SMMTSummit Therapeutics Inc
$ 23.47
(-36.05%)
24.67M
GNLNGreenlane Holdings Inc
$ 0.012699
(-15.34%)
355.22M
AGMHAGM Group Holdings Inc
$ 0.0477
(22.31%)
340.91M
OMEXOdyssey Marine Exploration Inc
$ 1.4979
(75.79%)
285.65M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 10.455
(19.62%)
266.95M
RTCBaijiayun Group Ltd
$ 0.3244
(74.88%)
263.23M

NMRA Discussion

View Posts
investorcg investorcg 2 months ago
$NMRA . Trades below CASH. 7 drugs in pipeline. Recently took a 80% haircut on bad initial data on one of three phase III. Oversold. RSI low. Bounce.
👍️0
glenn1919 glenn1919 3 months ago
nmra...................................under 2
👍️0
glenn1919 glenn1919 4 months ago
NMRA........................https://stockcharts.com/h-sc/ui?s=NMRA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
NMRA.............................................https://stockcharts.com/h-sc/ui?s=NMRA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
nmra..........................under 2.00
👍️0
TheFinalCD TheFinalCD 4 months ago
1.95 -81%
$NMRA P2b retrospective data mining in shock turn of events doesn't translate to prospective P3 stat sig data. What a surprise.— Biotech Shoutouts (@BiotechSho99376) January 2, 2025
$NMRA right to cash level, same drug bi polar next pic.twitter.com/nfXRhMULQH— MonkeyGenius (@bearsbounce) January 2, 2025
$NMRA whiff - pic.twitter.com/y0cVEhb2fN— Sports_Bios (@Sports_bios) January 2, 2025
👍️0
Monksdream Monksdream 6 months ago
NMRA under $15
👍️0
Monksdream Monksdream 10 months ago
NMRA under $10
👍️0
Monksdream Monksdream 12 months ago
NMRA under &10
👍️0

Your Recent History

NASDAQ
NMRA
Neumora Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads